Trimetazidine reduces the degree of fibrosis in alkali burns of the esophagus.
OBJECTIVE
The aim of this study was to investigate the efficacy of trimetazidine (TMZ), an antioxidant agent, on the prevention of stricture development after esophageal caustic injuries in rat.


METHODS
Thirty rats were divided into 3 equal groups. A standard esophageal caustic burn was produced by application of 37.5% NaOH for a period of 90 seconds followed by water rinse. Group A (sham) animals were uninjured. Group B rats were injured but untreated. Group C rats were injured and received TMZ (5 mg/kg/d) via intraperitoneal route. Efficacy of the treatment was assessed in 28 days by measuring stenosis index and histopathologic damage score and by determining tissue hydroxyproline content.


RESULTS
The stenosis index in the TMZ-treated group was significantly lower than the untreated group, similarly in the sham laparotomy group (stenosis index: 0.34 +/- 0.10, 0.94 +/- 0.21, 0.38 +/- 0.05, respectively; P < .05). The hydroxyproline level (microgram per milligram of wet tissue) was significantly lower in the TMZ-treated group compared with untreated group, similarly in the sham laparotomy group (1.06 +/- 0.14, 1.33 +/- 0.08, 0.68 +/- 0.15 microg/mg wet tissue, respectively; P < .05). In the untreated group, histopathologic damage score was significantly higher than TMZ-treated group (P < .05).


CONCLUSIONS
Trimetazidine reduces the degree of fibrosis and ameliorates histopathologic damage in experimental model of corrosive esophagitis in rats.
Yukselen
Vahit
V
Department of Gastroenterology, Adnan Menderes University School of Medicine, 09100 Aydin, Turkey. yukselenvahit@yahoo.com
Karaoglu
Ali Onder
AO
Yenisey
Cigdem
C
Tuncyurek
Muge
M
Ozutemiz
Omer
O
D000818:Animals; D002057:Burns, Chemical / Q000188:drug therapy* / Q000473:pathology; D002424:Caustics / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D004940:Esophageal Stenosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004947:Esophagus / Q000737:chemistry / Q000473:pathology; D005355:Fibrosis; D006909:Hydroxyproline / Q000032:analysis; D007274:Injections, Intraperitoneal; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012972:Sodium Hydroxide / Q000633:toxicity*; D014292:Trimetazidine / Q000008:administration & dosage / Q000627:therapeutic use*
D002424:Caustics; D012972:Sodium Hydroxide; D014292:Trimetazidine; D006909:Hydroxyproline